Mycophenolate Mofetil Appears Effective for the Treatment of Patients With Refractory Crohn’s Disease
MMF resulted in clinical, endoscopic, and biochemical benefits in some patients with refractory CD, and was tolerated by most patients. Further randomized controlled trials are needed to define optimal dosing and long-term efficacy and safety.
Authors
- Kendra Kamp (ORCID: https://orcid.org/0000-0002-7753-3564)
- Mitra Barahimi
- Sam Rosenfeld
- Jason Brian Harper (ORCID: https://orcid.org/0000-0003-2722-8534)
- Kindra Clark‐Snustad (ORCID: https://orcid.org/0000-0003-1948-0780)
- Jeffrey Jacobs (ORCID: https://orcid.org/0000-0001-9066-5900)
- Scott D. Lee (ORCID: https://orcid.org/0000-0001-8936-8052)
Institutions
- University of Washington (US)
Publication Details
- Journal
- Crohn s & Colitis 360
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1093/crocol/otae067
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- National Institute of Nursing Research